KR20220050905A - L-dopa-유도된 운동이상증의 예방적 및/또는 치료적 처치에 사용하기 위한 약제학적 조성물 - Google Patents

L-dopa-유도된 운동이상증의 예방적 및/또는 치료적 처치에 사용하기 위한 약제학적 조성물 Download PDF

Info

Publication number
KR20220050905A
KR20220050905A KR1020227006569A KR20227006569A KR20220050905A KR 20220050905 A KR20220050905 A KR 20220050905A KR 1020227006569 A KR1020227006569 A KR 1020227006569A KR 20227006569 A KR20227006569 A KR 20227006569A KR 20220050905 A KR20220050905 A KR 20220050905A
Authority
KR
South Korea
Prior art keywords
dopa
dyskinesia
pharmaceutical composition
fasudil
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227006569A
Other languages
English (en)
Korean (ko)
Inventor
아나 엠. 무뇨스 파티뇨
호세 루이스 라반데이라 가르시아
안드레아 로페스 로페스
Original Assignee
유니버시다데 데 산티아고 데 콤포스텔라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시다데 데 산티아고 데 콤포스텔라 filed Critical 유니버시다데 데 산티아고 데 콤포스텔라
Publication of KR20220050905A publication Critical patent/KR20220050905A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227006569A 2019-07-31 2020-07-24 L-dopa-유도된 운동이상증의 예방적 및/또는 치료적 처치에 사용하기 위한 약제학적 조성물 Pending KR20220050905A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201930713A ES2804076B2 (es) 2019-07-31 2019-07-31 Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa
ESP201930713 2019-07-31
PCT/ES2020/070482 WO2021019116A1 (es) 2019-07-31 2020-07-24 Composición farmacéutica para su uso en el tratamiento profiláctico y/o terapéutico de discinesias inducidas por l-dopa

Publications (1)

Publication Number Publication Date
KR20220050905A true KR20220050905A (ko) 2022-04-25

Family

ID=74229008

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006569A Pending KR20220050905A (ko) 2019-07-31 2020-07-24 L-dopa-유도된 운동이상증의 예방적 및/또는 치료적 처치에 사용하기 위한 약제학적 조성물

Country Status (8)

Country Link
US (2) US11337985B2 (cg-RX-API-DMAC10.html)
EP (1) EP4005574B1 (cg-RX-API-DMAC10.html)
JP (2) JP7780420B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220050905A (cg-RX-API-DMAC10.html)
CN (1) CN114401725A (cg-RX-API-DMAC10.html)
CA (1) CA3145360A1 (cg-RX-API-DMAC10.html)
ES (2) ES2804076B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021019116A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Also Published As

Publication number Publication date
EP4005574C0 (en) 2024-07-03
JP2022542305A (ja) 2022-09-30
US11337985B2 (en) 2022-05-24
CN114401725A (zh) 2022-04-26
ES2804076B2 (es) 2021-07-12
ES2987334T3 (es) 2024-11-14
US12465613B2 (en) 2025-11-11
CA3145360A1 (en) 2021-02-04
EP4005574A4 (en) 2023-05-24
US20220211719A1 (en) 2022-07-07
WO2021019116A1 (es) 2021-02-04
EP4005574A1 (en) 2022-06-01
EP4005574B1 (en) 2024-07-03
US20210393646A1 (en) 2021-12-23
JP7780420B2 (ja) 2025-12-04
ES2804076A1 (es) 2021-02-03
JP2025169440A (ja) 2025-11-12

Similar Documents

Publication Publication Date Title
Lu et al. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation
Levandis et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
Gardoni et al. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
Fiorentini et al. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease
Bordia et al. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease
Qin et al. Nuclear factor-κB contributes to excitotoxin-induced apoptosis in rat striatum
Decressac et al. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
US10751320B2 (en) Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders
Fuzzati‐Armentero et al. Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates L‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease
JP2025169440A (ja) L-ドパ誘発性ジスキネジアの予防的及び/又は治療的処置において使用するための医薬組成物
Sasaki et al. Evaluation of canthinone alkaloids as cerebral protective agents
Wu et al. Ecdysterones from Rhaponticum carthamoides (Willd.) Iljin reduce hippocampal excitotoxic cell loss and upregulate mTOR signaling in rats
Park et al. Epigenetic and metabolic changes in diffuse intrinsic pontine glioma
Tronci et al. Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats
Lenda et al. Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
US20040127571A1 (en) Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
Agnati et al. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson’s disease
Bagetta et al. Lack of involvement of nitric oxide in the mechanisms of seizures and hippocampal damage produced by kainate and ouabain in rats
Michel et al. Synergistic differentiation by chronic exposure to cyclic AMP and nerve growth factor renders rat phaeochromocytoma PC12 cells totally dependent upon trophic support for survival
Ba et al. Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model
Hwang et al. Changes in the levels of low molecular weight metabolites in the mouse cerebellum following treatment with methylmercury
RU2662429C1 (ru) Пептид, обладающий нейропротекторной активностью на модели МФТП-индуцированного паркинсонизма и фармацевтическая композиция на его основе
Spinnewyn et al. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease
EP4277620A1 (en) Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of fatty liver disease
Dincer Pharmacoepigenetics of Memantine in Dementia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000